Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sex-linked Disorders01:43

Sex-linked Disorders

103.7K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
103.7K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.1K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.1K
X-linked Traits01:19

X-linked Traits

55.8K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
55.8K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

93
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
93
Cross-bridge Cycle01:26

Cross-bridge Cycle

118.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
118.7K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AAV-mediated gene transfer of a novel microdystrophin ameliorates pathology and enhances muscle function in a mouse model of DMD.

Molecular therapy. Nucleic acids·2026
Same author

Liver health in myotubular and centronuclear myopathies: a patient-driven data collection study to better understand liver health and improve standards of care.

Neuromuscular disorders : NMD·2026
Same author

AAV8 gene therapy and dietary insults together precipitate cholestatic liver disease in a mouse model of X-linked myotubular myopathy.

Science translational medicine·2026
Same author

Establishment of normal myofiber size distribution in children and young adults.

Journal of neuropathology and experimental neurology·2025
Same author

Myosin inhibition partially rescues the myofiber proteome in X-linked myotubular myopathy.

JCI insight·2025
Same author

Screening rare genetic diagnoses for amenability to bespoke antisense oligonucleotide therapy development: A retrospective cohort study.

Genetics in medicine : official journal of the American College of Medical Genetics·2025
Same journal

Aquatic training improves muscle strength and functional mobility in adults with myotonic dystrophy type 1: a pilot randomized trial.

Neuromuscular disorders : NMD·2026
Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026
Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026
Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026
See all related articles

Related Experiment Video

Updated: Oct 14, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.6K

X-linked myotubular myopathy.

Michael W Lawlor1, James J Dowling2

  • 1Department of Pathology and Laboratory Medicine and Neuroscience Research Center, Medical College of Wisconsin, Milwaukee, WI, USA.

Neuromuscular Disorders : NMD
|November 5, 2021
PubMed
Summary
This summary is machine-generated.

X-linked myotubular myopathy (XLMTM) is a severe genetic muscle disorder. This review covers its pathology, mechanisms, and recent therapeutic advancements for this debilitating condition.

More Related Videos

Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

40.6K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.2K

Related Experiment Videos

Last Updated: Oct 14, 2025

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

15.6K
Tissue Triage and Freezing for Models of Skeletal Muscle Disease
05:58

Tissue Triage and Freezing for Models of Skeletal Muscle Disease

Published on: July 15, 2014

40.6K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.2K

Area of Science:

  • Biochemistry
  • Genetics
  • Pathology

Background:

  • X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disease.
  • It stems from mutations in the MTM1 gene, encoding the myotubularin (MTM1) phosphatase.
  • XLMTM causes profound muscle weakness, disability, and early mortality.

Purpose of the Study:

  • To review the clinical and pathological features of XLMTM.
  • To discuss the underlying pathomechanisms of the disease.
  • To highlight recent progress in therapeutic strategies for XLMTM.

Main Methods:

  • Literature review of clinical studies and research.
  • Analysis of pathological findings from muscle biopsies.
  • Synthesis of current knowledge on disease mechanisms and therapies.

Main Results:

  • XLMTM is characterized by specific muscle biopsy findings like central nuclei and myofiber hypotrophy.
  • MTM1's role in dephosphorylating PI3P and PI3,5P2 is crucial.
  • Advances in therapy development are emerging for this condition.

Conclusions:

  • Understanding XLMTM's clinical, pathological, and mechanistic aspects is key.
  • Therapeutic development offers hope for patients with this severe genetic disorder.